Mirum Pharmaceuticals : MIRM

MIRM

Stock Data

$96.53

$0.78 (0.80%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Mirum Pharmaceuticals Inc is a pioneering biopharmaceutical firm dedicated to creating innovative treatments for rare and orphan diseases. With a focus on liver disorders, its flagship product, LIVMARLI, is an oral medication aimed at combating progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia. Additionally, Mirum is advancing Volixibat, targeting adult primary sclerosing cholangitis and primary biliary cholangitis. Founded in 2018, Mirum is based in Foster City, California, demonstrating a commitment to addressing unmet medical needs in the realm of liver disease.

All Mirum Pharmaceuticals Articles

1 Article

Trey Thoelcke | Jan 31, 2026 at 8:15 AM EST

Insiders Are Still Scooping Up Under Armour and WR Berkley Shares

Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares…

Mirum Pharmaceuticals : MIRM

MIRM

$96.53

All Mirum Pharmaceuticals Articles

Insiders Are Still Scooping Up Under Armour and WR Berkley Shares

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Mirum Pharmaceuticals : MIRM

MIRM

$96.53

All Mirum Pharmaceuticals Articles

Insiders Are Still Scooping Up Under Armour and WR Berkley Shares

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s